A searching for some possibilities how to increase DOX efficacy in cancer cells and minimizing associated toxicities to non-cancerous tissues is in the forefront of scientific research. This study showed that isoquinoline derivative oracin significantly increased antiproliferative effect of cytostic drug doxorubicin in cancer cells and simultaneously decreased its toxicity in non-tumorous cells.